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Epigenetic control in rheumatoid arthritis synovial fibroblasts
Abstract
Rheumatoid arthritis synovial fibroblasts (RASFs) are the effector cells of cartilage and bone
destruction. These cells show an 'intrinsically' activated and aggressive phenotype that results in the
increased production of matrix-degrading enzymes and adhesion molecules, and is conserved over
long-term passage in vitro. The three main mechanisms of epigenetic control -- DNA methylation,
histone modifications and microRNA activity -- interact in the development of the RASF phenotype.
The extent of global DNA methylation is reduced in synoviocytes in situ and RASFs in vitro. In
addition, histone hyperacetylation occurs and specific microRNAs are expressed in RASFs. Normal
synovial fibroblasts cultured in a hypomethylating milieu acquire an activated phenotype similar to that
of RASFs. These findings suggest that epigenetic control, in particular the control of DNA methylation,
is deficient in RASFs. Genome-wide analyses of the epigenome will enable the detection of additional
genes involved in the pathogenesis of rheumatoid arthritis, the identification of epigenetic biomarkers,
and potentially the development of a therapeutic regimen that targets activated RASFs.
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synovial fibroblasts
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Abstract | rheumatoid arthritis synovial fibroblasts (rAsFs) are the effector cells of cartilage and bone 
destruction. These cells show an ’intrinsically’ activated and aggressive phenotype that results in the increased 
production of matrix‑degrading enzymes and adhesion molecules, and is conserved over long‑term passage 
in vitro. The three main mechanisms of epigenetic control—DNA methylation, histone modifications and 
microrNA activity—interact in the development of the rAsF phenotype. The extent of global DNA methylation 
is reduced in synoviocytes in situ and rAsFs in vitro. in addition, histone hyperacetylation occurs and specific 
microrNAs are expressed in rAsFs. Normal synovial fibroblasts cultured in a hypomethylating milieu acquire 
an activated phenotype similar to that of rAsFs. These findings suggest that epigenetic control, in particular 
the control of DNA methylation, is deficient in rAsFs. Genome‑wide analyses of the epigenome will enable 
the detection of additional genes involved in the pathogenesis of rheumatoid arthritis, the identification of 
epigenetic biomarkers, and potentially the development of a therapeutic regimen that targets activated rAsFs.
Karouzakis, e. et al. Nat. Rev. Rheumatol. 5, 266–272 (2009); doi:10.1038/nrrheum.2009.55
Introduction
Diseases such as cardiovascular, metabolic, musculo­
skeletal and hematopoietic disorders, which can be 
attributed to the interaction between genetic and 
environ mental factors as well as to processes of aging, 
are highly prevalent in industrialized nations and can be 
associated with a large burden on health­care resources. 
Many of these  diseases are thought to have a clear epi­
genetic background, as in pediatric developmental and 
imprinted  diseases,1,2 and/or to be influenced by environ­
mental factors, as in the contribution of smoking to the 
development of rheumatic diseases and atherosclerosis.3 
Metabolic disorders (for example, obesity and diabetes)4 
and neuro degenerative disorders such as Alzheimer 
disease and dementia5 can also have an epigenetic compo­
nent. The prevalence of some of these diseases differs 
according to sex; for example, rheumatoid arthritis (RA) 
is more common in women than in men, whereas athero­
sclerosis shows the reverse pattern.6 With aging, these sex­
related differences become less obvious. An interesting 
question is whether sex differences in disease prevalences 
in middle­aged adults could be associated with differen­
tial imprinting of the X­chromosome—an epigenetic pro­
cess—since one X­chromosome in women should always 
be inactivated by DNA methylation. In systemic lupus 
erythematosus, the demethylation of specific sequences 
in the X chromosome could contribute to the female pre­
dominance of the disease. CD40LG, which is located on 
the X chromo some, is demethylated in the CD4+ T cells of 
women with systemic lupus erythematosus,7 which leads 
to the  over expression of CD40 ligand on these cells.
The term epigenetics refers to all meiotically and mito­
tically heritable changes in gene expression that are not 
coded in the DNA sequence itself. Three inter acting epi­
genetic mechanisms, namely DNA methylation, histone 
modification and complementary microRNA (miRNA) 
binding, initiate and sustain gene silencing and expres­
sion. These systems integrate genetic background and 
environmental factors to enable cell adaptation and sur­
vival (Figure 1). The disruption of one or another of these 
interacting systems can lead to inappropriate expression 
or silencing of genes, and result in ‘epigenetic diseases’ 
that include various types of cancer and potentially 
 autoimmune disorders.8
Methylation of DNA prevents the access of transcription 
factors and inactivates gene transcription. DNA methy­
lation involves the addition of a methyl group in the 5' 
position of the cytosine base­pair ring, which results in 
the formation of 5­methylcytosine.9 This enzymatic reac­
tion is catalyzed by DNA methyltransferase 1 (DNMT1). 
In somatic cells, DNMT1 is responsible for maintaining 
methylation patterns during replication in the context 
of cytosine–phosphate–guanine (CpG) dinucleotides.10 
During embryogenesis, DNA methyltransferases 3a and 3b 
(DNMT3a and DNMT3b) add new methylation patterns 
to the initially methylated CpG dinucleotides in the DNA 
that silence the transcription of specific gene regions.11 
Most single CpG dinucleotides in the genome are methy­
lated, including those in retro transposable elements, Alu 
sequences and α­satellite repeats. By contrast, genomic 
regions with a high frequency of CpG di nucleotides—
termed CpG islands—remain un methylated. CpG 
islands in promoter regions of tumor­suppressor genes 
are, however, methylated and silenced in diseases such 
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as cancer.12 Methyl­CpG­binding domain (MBD) pro­
teins, including MBD1, MeCP2, MBD3, and MBD4, have 
important roles in the mechanism of DNA methy lation 
and interact with histone deacetylases to change the 
 chromatin structure.13
DNA methylation has a fundamental role in cell dif­
ferentiation, embryonic development, X­chromosome 
inactivation in women, genomic imprinting, cell repro­
gramming and the silencing of retroviral elements such as 
lINe­1 (long interspersed nuclear element 1).8 The DNA 
methylation machinery is deregulated in several types 
of pathology, including developmental, inflam matory 
and autoimmune disorders.14 In addition to promoter 
hypermethylation, these diseases can also be caused by 
mechanisms such as loss of imprinting, deficient DNMT 
activity (secondary to post­translational modifications of 
the protein or through the action of specific miRNAs) or 
mutation of an MBP. In this Review, we focus on epi genetic 
control in RA synovial fibroblasts (sFs).
Mesenchymal stem cell differentiation
Mesenchymal stem cells (MsCs) are undifferentiated, 
multi potent cells that reside in various human tissues 
and have the potential to differentiate into osteoblasts, 
chondro cytes, adipocytes, fibroblasts and other cells of 
mesenchymal origin. In the human body they can be 
regarded as readily available reservoirs of reparative cells 
that are capable of mobilizing, proliferating and differen­
tiating into the appropriate cell type in response to certain 
environmental signals.15 MsCs contain an intrinsically 
predefined, uni directional differentiation program. The 
develop mental fate of an MsC is, therefore, dependent 
on the general potential of the cell as well as on micro­
environmental cues such as stimulation from growth 
factors. During the normal differentiation of MsCs into 
fibroblasts, two key transition points are regulated by epi­
genetic processes: first, the development of MsCs into a 
transient fibroblastic pheno type, and, second, the termina­
tion of lineage expansion. Both of these transition points 
are tightly regulated in space and time. For example, MsCs 
that develop into adipocytes are epigenetically marked by 
mosaic hypo methylation of adipo genic pro moters, whereas 
pro moters in these cells specific to a non adipogenic lineage 
are hyper methylated.16 Furthermore, the terminal differen­
tiation of fibroblastic adipocytes into osteoblasts involves 
histone modifications.17 A similar hypothesis is that sFs 
emerge from MsCs and develop into tissue­specific cells 
under the influence of the microenvironment and under 
epigenetic control (Figure 2).
Fibroblasts and phenotypic plasticity
Fibroblasts are metabolically active cells that have criti­
cal roles in the regulation of extracellular matrices, inter­
stitial fluid volume and pressure, and wound healing. 
During tissue repair, for instance, fibroblasts undergo 
a change in state from their normal, relatively quies­
cent phenotype, in which they are involved in the slow 
 turnover of the  extracellular matrix, to a proliferative and 
Key points
rheumatoid arthritis synovial fibroblasts (rAsFs) exhibit an aggressive  ■
phenotype that is characterized by the expression of matrix‑degrading enzymes 
and adhesion molecules
The aggressive rAsF phenotype can be induced in normal synovial fibroblasts  ■
by culture in a hypomethylating milieu
Histone modifications and microrNA binding have also been implicated in  ■
the development of rAsF phenotype, which suggests that all three epigenetic 
pathways are altered in rheumatoid arthritis
whole‑epigenome analysis could lead to the discovery of novel genes and  ■
epigenetic biomarkers involved in the pathogenesis of rheumatoid arthritis, 
with potential implications for treatment
contractile phenotype termed myofibroblasts.18 These myo­
fibroblasts show some of the phenotypic characteristics of 
 smooth­muscle cells
Fibroblasts are thought to develop specific charac­
teristics in response to their microenvironment; for 
example, fibroblasts in the skin, spleen, kidney, lung or 
synovium exhibit different patterns of growth factor 
release.18 To produce such characteristics, certain genes 
are silenced in fibroblasts in some tissues but expressed 
in those in other tissues. In the synovium, as is the case in 
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Figure 1 | epigenetic regulation of gene expression integrates both genetic and 
environmental factors. epigenetics involves three interrelated mechanisms: DNA 
methylation, histone modifications and the activity of mirNAs. DNA methylation 
occurs in CpG islands within gene sequences and results in their transcriptional 
silencing. Histone modifications alter chromatin structure through acetylation 
(associated with gene expression) or deacetylation (associated with gene 
silencing). The mirNAs are encoded within the genome and their expression is 
regulated by other epigenetic mechanisms. each mirNA binds to a specific 3' 
untranslated region of an mrNA and inhibits its translation to protein. All three 
epigenetic mechanisms can be influenced by environmental factors such as 
nutrition and smoking. Abbreviations: CpG, cytosine–phosphate–guanine;  
DNMT, DNA methyltransferase; HAT, histone acetylase; HDAC, histone deacetylase; 
MBP, methyl‑binding protein; MeC, 5‑methylcytosine; mirNA, microrNA;  
mrNA, messenger rNA.
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other compartments, tissue­specific genes are expressed. 
These patterns of gene expression are, in great part, under 
epigenetic control.
Many diseases are associated with deregulation of the 
injury–repair response and fibroblast function, which leads 
to an increase or decrease in the deposition of extracellular 
matrix proteins, altered tissue architecture, impaired func­
tion and, in some cases, substantial morbidity and mor­
tality, as in systemic sclerosis. In such cases, the fibroblasts 
are hypothesized to either not react or overreact to a given 
stimulus; this incorrect response can have different causes, 
including deregulated epi genetic control.
Synovial fibroblasts in RA
In RA, a cytokine­independent pathway seems to be 
responsible for the ongoing joint destruction mediated 
by sFs.19 The pathological changes associated with this 
process include excessive hyperplasia of and an infiltration 
of inflammatory cells into the synovial tissue. Activated sFs 
have an important role in the destruction caused by this 
disease; however, myofibroblasts have also been detected in 
the RA synovium, which reflects either an activation state 
or a problem of differentiation.20 The activated phenotype 
of RAsFs could be an intrinsic property of these cells, since 
RAsFs co­implanted with human cartilage into severe, 
combined immunodeficient (sCID) mice are invasive 
even in the absence of other cells of the human immune 
system.21 This concept is reflected in vitro by, for example, 
the increased production of matrix­degrading enzymes 
and adhesion molecules by RAsFs. The ‘imprinted’ aggres­
sive and invasive phenotype of RAsFs could be determined 
by genetic and/or epigenetic backgrounds, perhaps in the 
context of global genomic hypomethylation.
sFs, more so than other types of fibroblasts, acquire 
pheno typic characteristics that are commonly associ­
ated with transformed cells, including the capacity for 
 anchorage­independent growth.22 In contrast to normal 
sFs or those from patients with osteoarthritis, sFs from 
patients with RA show ‘spontaneous’ activities that 
are associated with an aggressive phenotype.21,23–25 For 
example, these cells show upregulated expression of proto­
oncogenes,21 specific matrix degrading enzymes,23 adhe­
sion molecules,24 and cytokines.25 These observations of 
an intrinsically activated cellular phenotype prompted 
us and others to search for possibly causative epigenetic 
modifications (Figure 3). Histone acetylation is increased 
in RAsFs and specific miRNAs are upregulated,26,27 which 
suggests that other epigenetic pathways as well as genomic 
methylation are altered.
Epigenetic processes in the pathogenesis of RA
Global genomic hypomethylation
our group and others28,29 have reported that the endoge­
nous retroviral element lINe­1 is reactivated in the RA 
synovial lining and at sites of cartilage and bone invasion. 
Most lINe­1 elements are retrotransposition­defective. A 
full­length lINe­1 messenger RNA has been isolated from 
RAsFs that encoded an intact open reading frame (oRF) 1; 
oRF2, however, contained multiple stop codons,30 which 
rendered the entire element retro transposition­defective. 
We suggested that the expression of lINe­1 proteins 
in RAsFs is associated with a partially hypomethylated 
promoter region. The degree of hypomethylation in the 
lINe­1 promoter is under investigation.31 In normal cells, 
repetitive sequences such as lINe­1, Alu, and α­satellite 
repeats are silenced by methylation, and their expression 
can reflect global DNA hypomethylation.32 This general 
cellular mechanism has important consequences in 
RAsFs because methy lation markers apparently cannot 
be correctly trans mitted from mother to daughter cells 
during proliferation. The incorrect methy lation patterns 
induce either cellular de differentiation or a completely 
new phenotype.
These reports suggest that global genomic hypo methy­
lation has a role in the pathogenesis of RA, and that 
genes normally silenced by methylation might contrib­
ute to the activated phenotype of RAsFs. For example, 
the gene that encodes interleukin (Il)­6 could be regu­
lated by demethylation of a single CpG site in the IL6 
promoter region.33
DNA methyltransferases
In somatic cells, DNMT1 is the predominant DNA methyl­
transferase. Reduction of DNMT1 levels leads to hypo­
methylation, genomic instability, and tumorigenesis.34 The 
direct interaction between DNMT1 and proliferating cell 
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Synovial
fibroblast
Rheumatoid
arthritis synovial
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Tissue-type-specific
gene expression
Release of chemokines, growth factors, cytokine receptors,
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Figure 2 | Differentiation of mesenchymal stem cells into 
fibroblasts is under epigenetic control, mainly via methylation 
or demethylation of specific promoter regions, which either 
enables or disables the expression of the relevant gene. 
Further development of fibroblasts into tissue‑specific cells 
is associated with additional methylation changes to gene 
promoter regions. A working hypothesis is that aggressive 
rheumatoid arthritis synovial fibroblasts emerge as a 
consequence of deregulated epigenetic mechanisms. 
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nuclear antigen ensures that patterns of methylation are 
faithfully preserved in DNA synthesis.11 A cause must, 
therefore, be found for the hypomethylation observed in 
RAsFs. It could be the result of a deficiency of DNMTs 
and/or MBPs.35
other diseases have also been associated with decreased 
activity of DNMTs. For example, ICF (immuno deficiency, 
centromeric region instability and facial anomalies) syn­
drome is an autosomal­recessive disease that is associ­
ated with abnormal DNA methylation and mutations in 
the cata lytic domain of DNMT3b.36 The disease causes 
immuno deficiency as a result of reduced immuno­
globulin levels, and involves chromosomal instability due 
to hypomethylation of satellite repeats.
Influence of a hypomethylating milieu
With regard to the potential role of genomic hypo­
methylation in generating aggressive sFs, we hypothe sized 
that the RAsF phenotype could be mimicked in normal 
sFs by inhibition of DNMT1, for example by chronic 
treatment with a nontoxic dose of the DNA methyl­
transferase inhibitor azacytidine.35,37 In the study, about 
200 genes were found to be upregulated more than twofold 
by DNA hypomethylation, which was associated with 
enhanced protein expression in most cases. Furthermore, 
hypomethylation led to irreversible phenotypic changes 
in normal sFs, so that they resembled activated RAsFs. 
Proinflammatory cytokines such as tumor necrosis factor, 
Il­1β, and Il­6 have multiple influences on the patho­
genesis of RA; Il­1β38 and Il­639 can also affect genomic 
methylation. Il­6 stimulates translocation of DNMT1 
to the nucleus.40 An important point to note is that 
proinflam matory cytokines and growth factors accelerate 
the cell cycle. During DNA replication, normal sFs recruit 
DNMT1,37 which has been shown by Chuang and col­
leagues (in another system) to interact with proliferat ing 
cell nuclear antigen at the DNA replication fork to ensure 
the correct setting of methylation markers.41 In RAsFs, 
however, DNMT1 might be deficient, which would result 
in a gradual genomic hypo methylation, a process that 
would worsen with each cell cycle. A similar process has 
been reported in tumor cells, in which increased cell pro­
liferation and global genomic hypomethylation are accom­
panied by a relative deficiency in DNMT1.42 Reduced 
levels of DNMT1 can, however, also occur in normal cells, 
as in terminal differentiation of neuronal cells and myo­
blasts.43 In RAsFs, then, a relative deficiency of DNMT1 
could lead to loss of methylation markers in daughter 
cells, and induce the irreversible differentiation into an 
aggressive phenotype. IL6 hypomethylation has also been 
observed in peripheral blood mononuclear cells from 
patients with RA:33 the demethylation of a single CpG site 
in the promoter region of IL6 could be responsible for the 
overexpression of Il­6 in patients with RA.
hypermethylation of specific promoters
our work raises the question of whether global genomic 
hypomethylation is accompanied by or followed by 
specific promoter hypermethylation, as is the case in 
various tumors.12,44 At least one such example has been 
reported in the literature—hypermethylation silences the 
gene TNFRSF25, which encodes death domain receptor 3 
(DDR3; also known as tumor necrosis factor  receptor 
superfamily member 25).45 The promoter region of 
TNFRSF25 contains many CpG motifs, including a CpG 
island that is specifically hypermethylated in synovial cells 
isolated from patients with RA. Assays showed that this 
CpG island is essential for transactivation of TNFRSF25, 
and that forced hypermethylation of this CpG island in vitro 
(by means of the bacterial methylase sss I) inhibits expres­
sion of TNFRSF25. Furthermore, expression of DDR3 
protein was downmodulated in association with methy­
lation of this promoter CpG island in RAsFs.45 This mecha­
nism could explain, at least in part, the reported  relative 
resistance to apoptosis of RAsFs in certain patients.19
Investigating DNA methylation
The methods used to investigate DNA methylation can be 
divided into three categories: global methylation analy­
sis, single­locus analysis and whole­epigenome analysis 
(Figure 4).46
Global changes in DNA methylation are studied 
mainly by flow cytometry and immunohistochemistry 
(Figure 4a), which have been used to demonstrate DNA 
hypomethylation in RA synovium.
Analysis of a single epigenetic locus typically uses 
the technique of bisulfite modification sequencing 
(Figure 4b).47 This method detects and quantifies methy­
lation changes in, for example, CpG sites of gene pro moters. 
The assay is based on bisulfite­mediated conversion of 
unmethylated cytosine residues into uracil, whereas 
methylated cytosines remain unchanged; after polymerase 
chain reaction (PCR) amplification, unchanged cytosine 
residues in the nucleotide sequence indicate the presence 
of methylated cytosines, whereas conversion from cytosine 
Induction of DNA hypomethylation
  Specific promoter
methylation
Modification of histones
(acetylation–methylation)
Azacytidine
Transcription factors,
intracellular signaling
molecules
Synovial fibroblast
Normal fibroblast
Activated rheumatoid
arthritis synovial
fibroblasts
Figure 3 | The aggressive phenotype of rheumatoid arthritis synovial fibroblasts 
can be, in great part, reproduced by treating normal fibroblasts with a DNA 
methyltransferase inhibitor, such as azacytidine, which induces global DNA 
hypomethylation. The effects of hypomethylation might be direct, through the 
demethylation of the promoter regions of relevant genes, or indirect, through the 
activation of transcription factors, intracellular signaling molecules and/or even 
histone modifications.
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into thymidine indicates an unmethylated cytosine. 
This method has been used to demonstrate that lINe­1 
 promoters are hypomethylated in RAsFs.28 A related 
single­locus analysis technique used in clinical screen­
ing is pyrosequencing,48 a new DNA sequencing method 
based on detection of a light signal when nucleotides are 
incorporated into the DNA. Following PCR amplification 
of bisulfite­treated DNA, pyrosequencing of the specific 
product quantifies methylation by detecting each time a 
cytosine base is incorporated instead of a thymidine base. 
The advantages of this method are that multiple samples 
can be analyzed at the same time and that site­specific, 
quantitative, methylation information is obtained.
Alternatively, DNA methylation at a single locus can be 
analyzed in biopsy samples by use of methylation­sensitive 
endonucleases.49 Multiple enzymes that cleave different 
CpG sites in the promoter can be used to analyze DNA 
samples obtained from biopsy specimens. specific primers 
are designed to cover the CpG sites in the given gene and 
PCR is performed. Methylated DNA is resistant to enzy­
matic cleavage and will be amplified by PCR. Quantitative 
real­time PCR can be used.
Novel approaches to assessments of DNA methylation 
focus on global analyses of the epigenome by use of tiling 
arrays and CpG­island promoter arrays (Figure 4c).50 
Tiling arrays contain sets of oligonucleotides that span the 
entire human genome, or at least certain chromosomal 
regions of interest. CpG­island promoter arrays are based 
on probes located in the promoter regions of the human 
genome. In the study of RAsFs, progression from single­
locus analysis to whole­epigenome analyses in the near 
future will be an essential step.
Future directions
one of the most challenging problems in the field of epi­
genetics is the generation of detailed functional maps of 
the epigenome in health and disease, as well as in different 
cell and tissue types. This information will allow clini cians 
to tailor therapeutic regimens to the needs of an individual 
patient. An epigenetic disorder that affects, for example, 
the promoter of a given gene requires a thera peutic stra­
tegy different to that used to treat a disease with similar 
symptoms that is caused by a genetic mutation of the same 
gene. Differential diagnosis of such disorders, on the basis 
of epigenetic biomarker profiles in specific subgroups of 
patients, will, in turn, enable the development of drugs 
that target the defective epigenetic mechanism.
until recently, DNA methylation of promoter regions 
was investigated by time­consuming methods, such as 
bisulfite­modification sequencing, which are not suitable 
for large­scale analyses. With the rapid development of 
microarray platforms and high­throughput sequencing 
techniques, a global analysis of the epigenome to produce a 
detailed cartogram of each chromosome is now possible.49 
Information gathered by this approach should, however, 
be verified and complemented by detailed analyses that 
involve other techniques, such as bisulfite­modification 
sequencing, methylated CpG island recovery assay and 
methylated­DNA immunoprecipitation assays.51,52
Currently, the epigenome is not analyzed systematically, 
and epigenetic changes have not been assessed within the 
a
DNA
Global methylation analysis
b Single-locus methylation analysis
Bisulfite
conversion
PCR
A T A mC G A A T A C G A
c Whole-genome methylation analysis
Adaptor
ligation
Methylation-
dependent
digestion
Hybridization
with control DNA
PCR
Anti-MeC antibodies
MeC
A T A C G A A T A U G A
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CpG island 
microassay
Figure 4 | Methods used to analyze DNA methylation. 
a | Global methylation analysis employs anti‑MeC 
antibodies that immunoprecipitate methylated DNA. The 
purified, methylated DNA can then be amplified by PCr 
using primers specific for the gene of interest. b | The 
classic technique for single‑locus methylation analysis is 
bisulfite conversion and sequencing. A specific bisulfite 
primer is used with PCr to amplify a gene promoter in 
bisulfite‑modified genomic DNA. The PCr product is cloned 
to a vector and sequenced; the presence of T–G pairs is 
proof of an unmethylated gene sequence. c | CpG island 
microarrays can analyze methylation across the whole 
genome. such arrays consist of a library of human genome 
CpG‑island promoter regions. The array can be hybridized 
with immunoprecipitated, methylated DNA. Abbreviations: 
CpG, cytosine–phosphate–guanine; mC, 5‑methylcytosine; 
MeC, 5‑methylcytosine; PCr, polymerase chain reaction.
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Human Genome Project. evidence indicates, however, 
that several illnesses, including RA, are linked to specific 
epigenetic processes and profiles51 which, in the case of 
RA, might explain its late onset and the differences in 
age and sex distribution, as well as its progressive nature. 
Moreover, epigenetic alterations probably underpin 
the role of environmental factors in the pathogenesis of 
 diseases in genetically susceptible individuals, and thus 
might broaden the scope of new therapies.
Conclusions
The RA synovium contains cells of various types that 
exhibit hypomethylated DNA. Among these, RAsFs 
contain fewer 5­methylcytosine residues than normal sFs 
and this difference is conserved over long­term culture 
in vitro. Furthermore, expression of lINe­1 messenger 
RNA and proteins are associated with hypomethylated 
promoters. This characteristic reflects a global state of 
DNA hypomethylation, which has important conse­
quences for RAsFs, since an important mechanism of 
epigenetic control seems to be defective. As a demon­
stration of the consequences of this loss of epigenetic 
control, inhibition of DNMT1 expression in normal sFs 
is sufficient to produce an aggressive phenotype that 
includes upregulated expression of matrix­degrading 
enzymes and adhesion molecules. Indeed, the level of 
DNMT1 in proliferat ing RAsFs is lower than that in 
normal sFs. Thus, during DNA replication in RAsFs, 
the correct methylation patterns are not transmitted, or 
incorrect patterns are transmitted, from mother cells to 
daughter cells. Consequently, genes in the daughter cells 
that should be silenced are expressed. This mechanism 
explains in great part the high number of transcripts that 
are upregulated in RAsFs. 
several mechanisms can lead to the upregulation of 
gene transcripts as a consequence of DNA hypomethy­
lation, either directly, through the loss of methylation 
markers in gene promoter regions, or indirectly, through 
the action of transcription factors or signaling pathways 
that are modulated by methylation. since DNA methy­
lation interacts with histone modifications and miRNA 
activity, these other epigenetic mechanisms could also 
be affected and could contribute to development of the 
aggressive RAsF phenotype. The interplay between 
these epigenetic mechanisms should be investigated in 
this context. The progression from single­locus analysis 
of DNA methylation to whole­epigenome analysis will 
be important as the latter will enable the discovery of 
novel genes and epigenetic biomarkers involved in the 
pathogenesis of RA, and will help to expand the treatment 
options for this disease.
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